SME
IPO ·
NSE SME
Q-Line Biotech Ltd
Listed
Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, and distribut
Issue details
Price band
₹326 – ₹343
Face value
₹10
Lot size
400 shares
Minimum investment
₹2,74,400
Issue size
₹214.48 Cr
Fresh issue
₹203.74 Cr
Offer for sale
—
Issue type
Book Built
Exchange
NSE SME
Key dates
Opens
21 May 2026
Closes
25 May 2026
UPI mandate cut-off
5:00 PM on 25 May 2026
Allotment
26 May 2026
Refunds
27 May 2026
Shares in demat
27 May 2026
Listing
29 May 2026
Subscription and listing
Subscription
71.75x
Listing price
₹452
Registrar
Purva Sharegistry (India) Pvt Ltd
Lead manager
Hem Securities, Share India Capital Services
Subscription by category
Total
71.75x
Total applications
2,32,607
Anchor investors
Amount raised
₹61.10 Cr
Bid date
20 May 2026
50% lock-in ends
25 Jun 2026
Rest lock-in ends
24 Aug 2026
Listing day
Issue price
₹343
Open
₹452.00
High
₹474.60
Low
₹431.00
Day close
₹474.60
Listing gain at open
+31.78%
Issue structure
Shares reserved per category and share of the total issue
QIB Shares Offered
29,69,200
47.48%
Anchor Investor Shares Offered
17,81,200
28.48%
QIB (Ex. Anchor) Shares Offered
11,88,000
19.00%
NII Shares Offered
8,91,600
14.26%
bNII > ₹10L
5,94,400
9.51%
sNII < ₹10L
2,97,200
4.75%
Retail Shares Offered
20,79,200
33.25%
Market Maker Shares Offered
3,13,200
5.01%
Total Shares Offered
62,53,200
100.00%
Finaccle’s quick read
Neutral
FY25 income up 56%, PAT down 18%, ROE 16.88%, D/E 1.06, post-issue P/E 15.51x.
A rules-based screen of growth, margins, debt and valuation, built from the offer document and data on Chittorgarh.com. It is for information only and is not investment advice or a recommendation to buy or sell. Read the RHP and speak to a SEBI-registered adviser before you apply.
About the company
Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, and distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges.
Founded
Promoters
Promoter holding
Financial performance
Period
PAT
ROE
16.88%
ROCE
13.32%
Debt / equity
1.06
PAT margin
16.65%
P/E post issue
15.51
Market cap
₹800.16 Cr
Use of IPO money
To meet working capital requirements
₹93.50 Cr
Repayment of certain borrowing availed by the Company, in part or full
₹90.00 Cr
General Corporate Purposes
₹5.10 Cr
Issue Expenses
₹25.89 Cr
Strengths
✓
: Established manufacturing capabilities with focus on R&D, Reverse Engineering and quality control
✓
Long standing relationships with customers
✓
Revenue up 56% in FY25 to ₹322.58 Cr
✓
PAT margin of 16.65%
✓
ROE of 16.88% and ROCE of 13.32%
Risks to watch
!
PAT fell 18% in FY25
!
SME platform: large lot size and thinner trading liquidity
!
Debt to equity of 1.06
Planning to take your own company public?
Every listing on this page started with a growing business that got its numbers, governance and paperwork ready for investors. If you are a promoter weighing an SME or main board IPO, we can tell you where you stand and what it will take.
Talk to our IPO Advisory team for readiness planning, or our IPO Consultancy team to run the listing end to end.
Last updated:
Information is compiled from exchange notices and the company’s offer document. It is for general information only and is not investment advice or a recommendation to apply. Read the prospectus before investing.